The Effect of Hydration on the Main Adverse Cardiovascular and Cerebrovascular Events and Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention
Zhao Yingying,Bao Dan,Wang Xiaozeng,Han Yaling,Zhou Tienan,Gu Ruoxi,Zhang Quanyu
DOI: https://doi.org/10.3760/cma.j.issn.1673-8799.2019.03.001
2019-01-01
Abstract:Objective To evaluate the prognosis of hydration therapy on patients undergoing per-cutaneous coronary intervention(PCI) with iodixanol. Methods A retrospective study was performed on 3 042 cases of patients who were admitted from October 2013 to October 2015. All the patients were per-formed observation 72 hours after operation and 30 days after discharge. According to whether the patients received hydration treatment before surgery,they were divided into the hydration group and the non-hydra-tion group. There were 846 cases in the hydration therapy group,including 617 male cases and 229 female cases. There were 2 196 cases in the non-hydrated therapy group,including 1 596 male cases and 600 fe-male cases. The main endpoint event of this study was major adverse cerebrovascular events(MACCE)with-in 72 hours after PCI.MACCE was defined as target lesion revascularization,stroke,stent thrombosis,cardi-ac death,and myocardial infarction. The secondary endpoint was the incidence of MACCE and the incidence of contrast induced acute kidney injury(CI-AKI) within 30 days after surgery. Results (1) Baseline data of The two groups:there were significant differences between hydration therapy group and non-hydrated ther-apy group in age[(61.91 ± 10.61) years old,(63.43 ± 10.93) years old,P<0.001)],BMI [(25.19 ± 3.17) kg/m2 , (24.37 ± 3.11) kg/m2 , P <0.001 )], history of disease/surgery [ 91.84% ( 777/846 )、84.15% (1 848/2 196),P<0.001)],hyperlipemia[70.09% (593/846)、53.32% (1 171/2 196),P<0.001],diabetes mellitus[28.96% (245/846)、23.27% (511/2 196),P=0.001],β-blocker[38.77% (328/846)、44.99% (988/2 196),P=0.002],hypoglycemic agents[21.63% (183/846)、16.80% (369/2 196),P=0.002] and the obstruction of coronary artery disease(P<0.001). (2) Perioperative period and medication:PCI hydration capacity[(641.55 ± 358.52) ml,(813.20 ± 472.17)ml,P<0.001],and total hydration capacity[(1 113.60 ± 653.08)ml,(813.20 ± 472.17) ml,P<0.001] were differ between the groups.Significant differences were observed in: the dosage of iodixanol [( 153.29 ± 59.69 ) ml, (135.48 ± 56.42)ml,P<0.001],diuretic[1.18% (10/846)、3.42% (75/2 196),P<0.001],β-bloc-ker [ 14.89% ( 126/846 )、20.63% ( 453/2 196 ), P <0.001 ], and other drugs [ 62.17% (526/846 )、56.47% (1 240/2 196),P =0.004] between the two groups during intraoperation. (3) Main endpoint:MACCE occurred within 72 hours after surgery in 27 ( 3.19% ) patients in the hydration group and 44(2.00% )patients in the non-hydration group,including 27(3.19% ) patients in the hydration group, 1(0.05% )patients in the non-hydration group and 43(1.96% )patients in the myocardial infarction group. The difference was not statistically significant ( P >0.05).Secondary end points:72 hours after PCI to 30 days after MACCE,hydration group 1 case(0.12% ),the hydration group 5 cases(0.24% ),the hydra-tion group of myocardial infarction,1 case(0.12% ),1 case of nonhydratable group target essel revascular-ization(0.05% ),stent thrombosis in 1 case(0.05% ),3 cases(0.14% ),cardiac death differences had no statistical significance. The incidence of CI-AKI in the two groups within 72 hours after PCI was compared [7.09% (58/846)、8.15% (175/2 196)],and the difference was not statistically significant(P=0.339). Conclusion The safety of isosmotic contrast agent iodixanol is demonstrated again in Chinese PCI popula-tion and no adverse effect is observed of hydration therapy on patient prognosis.